A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff; Jake Shortt; Flora Yuen; John Reynolds; Hang Quach; Craig Wallington-Beddoe; Patricia Walker; Simon Harrison; Dunn Rosanne; Andrew Spencer

doi:10.1182/blood-2019-130084

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Anna Kalff, Jake Shortt, Flora Yuen, John Reynolds, Hang Quach, Craig Wallington-Beddoe, Patricia Walker, Simon Harrison, Dunn Rosanne, Andrew Spencer

College of Medicine and Public Health

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

BACKGROUND: KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD®-treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a kappa restricted MM population.

Original language	English
Article number	3144
Number of pages	4
Journal	Blood
Volume	134
Issue number	Supplement 1
DOIs	https://doi.org/10.1182/blood-2019-130084
Publication status	Published - 13 Nov 2019
Event	61st ASH Annual Meeting - Orlando, United States Duration: 7 Dec 2019 → 10 Dec 2019 Conference number: 61

Keywords

dexamethasone
lenalidomide
multiple myeloma
Antigens
hematotoxicity
thalidomide
abdominal pain
Kappa
Kappa Myeloma antigen (KMA)

Access to Document

10.1182/blood-2019-130084Licence: In Copyright

Cite this

Kalff, A., Shortt, J., Yuen, F., Reynolds, J., Quach, H., Wallington-Beddoe, C., Walker, P., Harrison, S., Rosanne, D., & Spencer, A. (2019). A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16). Blood, 134(Supplement 1), Article 3144. https://doi.org/10.1182/blood-2019-130084

@article{922196f2c353408480ccabe804af791f,

title = "A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)",

abstract = "BACKGROUND: KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD{\textregistered}-treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a kappa restricted MM population.",

keywords = "dexamethasone, lenalidomide, multiple myeloma, Antigens, hematotoxicity, thalidomide, abdominal pain, Kappa, Kappa Myeloma antigen (KMA)",

author = "Anna Kalff and Jake Shortt and Flora Yuen and John Reynolds and Hang Quach and Craig Wallington-Beddoe and Patricia Walker and Simon Harrison and Dunn Rosanne and Andrew Spencer",

year = "2019",

month = nov,

day = "13",

doi = "10.1182/blood-2019-130084",

language = "English",

volume = "134",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier B.V.",

number = "Supplement 1",

note = "61st ASH Annual Meeting ; Conference date: 07-12-2019 Through 10-12-2019",

}

Kalff, A, Shortt, J, Yuen, F, Reynolds, J, Quach, H, Wallington-Beddoe, C, Walker, P, Harrison, S, Rosanne, D & Spencer, A 2019, 'A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)', Blood, vol. 134, no. Supplement 1, 3144. https://doi.org/10.1182/blood-2019-130084

TY - JOUR

T1 - A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

AU - Kalff, Anna

AU - Shortt, Jake

AU - Yuen, Flora

AU - Reynolds, John

AU - Quach, Hang

AU - Wallington-Beddoe, Craig

AU - Walker, Patricia

AU - Harrison, Simon

AU - Rosanne, Dunn

AU - Spencer, Andrew

N1 - Conference code: 61

PY - 2019/11/13

Y1 - 2019/11/13

N2 - BACKGROUND: KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD®-treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a kappa restricted MM population.

AB - BACKGROUND: KappaMab is a chimeric IgG1 monoclonal antibody specific for Kappa Myeloma antigen (KMA), a tumour specific cell antigen exclusively expressed on the surface of kappa restricted MM cells. Early safety and efficacy signals seen with single-agent treatment in phase I/II studies in conjunction with observations that IMiD®-treatment upregulates the KMA target and enhances effector cell cytotoxicity, provide rationale for this proof-of principal immune-oncology (IO) approach in a kappa restricted MM population.

KW - dexamethasone

KW - lenalidomide

KW - multiple myeloma

KW - Antigens

KW - hematotoxicity

KW - thalidomide

KW - abdominal pain

KW - Kappa

KW - Kappa Myeloma antigen (KMA)

U2 - 10.1182/blood-2019-130084

DO - 10.1182/blood-2019-130084

M3 - Meeting Abstract

SN - 0006-4971

VL - 134

JO - Blood

JF - Blood

IS - Supplement 1

M1 - 3144

T2 - 61st ASH Annual Meeting

Y2 - 7 December 2019 through 10 December 2019

ER -

A Sequential Cohort Study Comparing Kappamab Alone to Kappamab, Lenalidomide and Low Dose Dexamethasone in Kappa-Restricted Relapsed Refractory Multiple Myeloma (AMaRC 01-16)

Abstract

Keywords

Access to Document

Fingerprint

Cite this